Cost-effectiveness of bevacizumab plus paclitaxel versus paclitaxel for the first-line treatment of HER2-negative metastatic breast cancer in specialist oncology centers in France

Cost-effectiveness of bevacizumab plus paclitaxel versus paclitaxel for the first-line treatment of HER2-negative metastatic breast cancer in specialist oncology centers in France

Abstract Background Evidence from clinical trials suggests that the addition of bevacizumab to chemotherapy in the first-line treatment of patients with HER2-negative metastatic breast cancer improves progression-free survival (PFS) but not overall survival (OS). However, a retrospective analysis of...

Full description

Bibliographic Details
Main Authors: Audrey Petitjean, Jayne Smith-Palmer, William Valentine, Bertrand Tehard, Stephané Roze
Format: Article
Language:English
Published: BMC 2019-02-01
Series:BMC Cancer
Subjects:
Cost
Cost-effectiveness
Breast cancer
Bevacizumab
France
Online Access:http://link.springer.com/article/10.1186/s12885-019-5335-8

Similar Items

Similar Items